desipramine and Pyrosis

desipramine has been researched along with Pyrosis in 1 studies

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.

Research

Studies (1)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Number of Enrolled Participants With Achalasia

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Anxiety and/or Depression

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Aperistalsis

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Belching Disorders

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Candida Esophagitis.

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Chronic Idiopathic Nausea

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Cyclic Vomiting Syndrome

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Distal Esophageal Spasm

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Eosinophilic Esophagitis

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Esophageal Ulceration.

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Functional Bloating

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Functional Diarrhea

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Functional Dysphagia

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Functional Gallbladder Disorder

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Functional Heartburn

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Functional Vomiting

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Gastric Outlet Obstruction

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Globus

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Hypertensive Peristalsis

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Ineffective Esophageal Motility

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Irritable Bowel Syndrome

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Jackhammer Esophagus

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Nutcracker Esophagus

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Rapid Contraction

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Reflux Esophagus.

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Unspecified Functional Bowel Disorder

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Weak Peristalsis I

(NCT01265550)
Timeframe: Screening

Number of Enrolled Participants With Weak Peristalsis II

(NCT01265550)
Timeframe: Screening

Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months

"Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months.~Failure; <50% improvement in the baseline GERD-HRQL score at 12 months or:~For patients randomized to Surgical Treatment: a.<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.~For patients randomized to Active Medical or Placebo Medical Treatment:~a.inability to tolerate both study medications or b.For patients treated with desipramine, i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit." (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Anxiety and/or Depression.

Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Belching Disorders

Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Chronic Idiopathic Nausea

Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Cyclic Vomiting Syndrome

Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Bloating

Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin

Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Diarrhea

Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Dysphagia

Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Gallbladder Disorder

Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Heartburn

Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Vomiting

Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Globus

Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Irritable Bowel Syndrome

Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Unspecified Functional Bowel Disorder

Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.

(NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.

(NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.

(NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.

(NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

Trials

1 trial available for desipramine and Pyrosis